Next Phase Newsletter

A Europe-based, global medical technology company formed by two medical device groups is actively seeking medical device investment opportunities. The firm typically invests early on in the development (series A or B) stage. The firm seeks to invest in the range of $1M-15M per company, though would pursue larger ($100M and up) deals if there were a strong rationale that would make the company an ideal, revenue-generating fit to the portfolio. The firm seeks to make 1-2 larger deals and 3-4 smaller ones within the next year and seeks investments globally.

The firm’s key focus areas are (1) neuromodulation (devices for epilepsy, obstructive sleep apnea, etc.), (2) cardiac surgery (heart valves, perfusion products), and (3) structural heart (transcatheter products for mitral, aortic, tricuspid repair and replacement). The call points that the firm targets are neurologists, ENTs; cardiac surgeons, cardiologists, and perfusionists.

The firm is not currently focused on therapeutics or lab equipment technology, though may be open to those used to assist procedures in the cardiovascular/neurostimulation space. The firm looks at both PMA and 510K devices, as it traditionally invests in PMA devices, and is now gaining an increasing interest in 510K devices.

The firm prefers experienced management teams, and may take a board or observer seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A digital health investment company launched in 2016 by a leading pharma and venture capital firm in the industry focuses on the digital health space ranging from therapeutics to diagnostic solutions in areas such as: precision medicine, behavioral health, wearables, and data analytics. The firm is seeking to make 6-8 new investments within the next two years. The firm’s investments range dependent on the opportunity, and focuses on investing in Seed to Series A rounds. For earlier stage companies, the firm has the ability to both lead and co-invest. The firm focuses on companies based in the U.S., but is open to invest globally.

The firm focuses on digital health technologies and solutions that aim to improve patient care and lifestyle. The firm is especially interested in technology with a software component, such as those that control patient care through monitoring medications and therapies, as well as technology with a big data component. The firm will only look at devices if they have an information component and/or generate data. The firm is also interested in technology with machine-learning applications. The firm is not interested in pure EMR or hospital IT systems. Based on all the criteria, the firm is indication agnostic.

The firm is a very active investor that seeks to be fully involved in their portfolio companies. The firm will take a board seat after the investment and will help companies fill management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund/family office based in Hangzhou, China currently manages two venture funds in addition to a number of private capital accounts through which investments are made – these two funds focus on life sciences. The firm primarily makes equity investments in early-stage rounds ranging from $1 million initially; for later-stage to pre-IPO companies, the firm looks to make initial equity investments ranging from $3-5 million. The firm looks for companies located around the globe, with a preference in the US and Europe (UK). Currently, the firm is also actively seeking in-licensing opportunities in biotech innovations that has a China angle. The firm is actively looking for investment opportunities.

The firm is a flexible and opportunistic investor and will consider therapeutics, medical devices, and diagnostics. The firm is open to all kinds of sectors and indications. For therapeutics, the firm has specific focuses on novel candidates for disease, PD1-base approaches, gene therapy, oncology, cardiovascular diseases, and small molecules. For medical devices, the firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is also interested in diagnostics although this area is less of a focus. In terms of therapeutics, the firm will look at products of pre-clinical stage and later stages from phase II to phase III. Regarding medical devices, the firm will invest at any stage of development.

The firm is looking for private companies only. The firm typically has no specific requirements for the management team, but this depends on how much the firm invests. The firm looks to take a board seat following the investment and is comfortable acting as both a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm headquartered in Tokyo, Japan with multiple offices throughout North America and Asia is currently making new investments from three main funds: SV5 Series (JPY 75 billion; 2016 vintage), Asia Technology Fund VI (USD 150 million; 2013), and Technology Partners V (USD 260 million; 2012). The firm has about JPY 429 billion AUM (USD 4.3 billion). The firm has a dedicated life science investment team and invests in venture stage companies. The firm invests in various stages, typically start-up and early stage. For life science companies, the firm generally allocates USD 3-5 million per round. The firm is currently focused on opportunities in the USA and Japan.

The firm invests opportunistically in the life sciences. The firm seeks to invest in innovative therapeutics, diagnostics, and medical devices. For therapeutics, the firm generally invests in novel platform technologies and considers both small molecules and biologics. The firm is indication agnostic and will consider orphan diseases. The firm is also agnostic to the stage of development, but typically invests in companies with a lead asset in clinical trials. For medical devices, the firm is also opportunistic and generally invests in devices that are in the clinic. The firm generally only invests in new IP/NCEs, and does not invest in repurposed or reformulated products.

The firm generally requires a seat on the board of directors or observers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An Asia-based global chemical company that serves the chemical, petrochemical and bioscience markets among other markets, has recently started a corporate venture initiative with a $300M budget to make strategic investments into both pre and post-commercial companies. The group is flexible in terms of structuring investments and may employ equity investments, M&A and licensing agreements. The group targets investment sizes from $100k – $5M for early stage companies and $10M – $50M for commercial-stage companies.

In terms of the healthcare and life science sectors, the group is most interested in companies working in diagnostics and research tools. The group is particularly interested in clinical diagnostics including IVDs and next generation platforms (NGS, liquid biopsy, LC-MS, point-of-care testing, digital PCR), separation media and connected devices and wearable medical sensors. The group is also interested in advanced materials including materials for secondary batteries, thin-film for electronic devices, separation (inorganic/organic/polymers) and composites. The group is agnostic to indication area, but has a particular interest in cancer, metabolic (including diabetes) and kidney disorders as well as reproductive health.

The group has no strict company or management team requirements and invest in both early and later stage opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A corporate venture capital arm of a Switzerland-based corporate manages a strategic fund aligned with the corporate’s strategy, focusing on oncology and infectious diseases. The fund serves two main purposes: to improve the patient journey (quality of life) and to improve drug development (patient recruitment, best responders, combination therapy). This is a $150M fund and invests in the range of $1M – $10M per company. The firm typically seeks to participate in Series A/B rounds, and is currently seeking 1-3 new equity opportunities a year. The firm supports the in-licensing activities of the corporate in the EU and U.S.

The firm is mainly seeking digital health and healthcare IT technologies, and additionally therapeutics and diagnostic proposals that relate to oncology and infectious diseases to support the corporate’s activities.

Within healthcare IT, the firm is seeking technologies at precommercial or commercial stage with potential customer traction that may use AI to integrate different data sources for patient monitoring, clinical decision support systems, digital therapeutics and solutions to improve drug development such as tools to optimize and accelerate patient recruitment and clinical development in general.

Within diagnostics, the firm is seeking molecular diagnostic tools in development stage which are strongly innovative (e.g. liquid biopsy) and have smart data components.

The firm is seeking oncology and infectious disease therapeutics to in-license.

The firm is very active and supportive with their portfolio companies. The firm typically seeks a board seat, and at times, also an observer seat. The firm is looking for experienced management team in the domain of focus and with entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A corporate venture arm of a large pharmaceutical company manages an evergreen fund and currently holds $750 million in assets under management. The fund invests separately from the corporate and is not mandated to invest in areas of strategic relevance with the corporate. The firm makes equity investments in early venture rounds. The firm typically invests up to $10M initially with a total of $15-25M going to a single company over multiple financing rounds. The firm is willing to both lead and co-invest in companies located around the globe and could make as many as 5-6 investments over the next year.

The firm invests in therapeutics, medical devices, and healthcare IT. The firm invests in early stages of development, from preclinical up to Phase IIa drug trials for therapeutics; and for medical devices the firm prefers to invest in companies that are anywhere from just starting a PMA study to on the market. The firm is interested in all classes and indications of therapeutics and devices with their main focus being that the technology be truly innovative and novel. They are not interested in cases of reformulations, re-purposing or “me too” ideas. The firm makes approximately 75% of its investment in therapeutics and 25% across medical devices, and healthcare IT although they are actively looking to increase exposure in these areas. The firm is also open to investing in laboratory equipment and drug development enabling technologies though this area is less of a focus.

The firm prefers to invest in management teams that have demonstrated prior success in the life science industry and are oriented on the goal of bringing a product to market. The firm is currently most interested in privately held companies and looks to take a board seat following investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com